Projected Income Statement: Yixintang Pharmaceutical Group Co., Ltd.

Forecast Balance Sheet: Yixintang Pharmaceutical Group Co., Ltd.

Forecast Balance Sheet - Yixintang Pharmaceutical Group Co., Ltd.
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Net Debt 1 -1,056 -2,174 -2,229 -1,917 -932 -2,322 -2,025 -2,479
Change - -105.87% -2.53% 14% 51.38% -149.15% 12.79% -22.42%
Announcement Date 3/14/22 3/17/23 3/19/24 4/27/25 4/28/26 - - -
1CNY in Million
Estimates

Cash Flow Forecast: Yixintang Pharmaceutical Group Co., Ltd.

Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
CAPEX 1 387.2 345.3 230.3 254.5 277.9 602.8 505 540.9
Change - -10.83% -33.31% 10.52% 9.21% 116.89% -16.23% 7.12%
Free Cash Flow (FCF) 1 - - 1,885 1,466 1,355 1,100 1,511 1,882
Change - - - -22.23% -7.54% -18.85% 37.36% 24.55%
Announcement Date 3/14/22 3/17/23 3/19/24 4/27/25 4/28/26 - - -
1CNY in Million
Estimates

Forecast Financial Ratios: Yixintang Pharmaceutical Group Co., Ltd.

Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028

Profitability

        
EBITDA Margin (%) 8.88% 8.67% 6.25% 10.13% 4.13% 11.67% 11.85% 12.73%
EBIT Margin (%) 7.31% 7.13% 5.66% 1.54% 2.44% 4.47% 4.73% 5.15%
EBT Margin (%) 7.52% 7.08% 4.04% 1.15% 2.35% 3.85% 4.32% 4.76%
Net margin (%) 6.32% 5.79% 3.16% 0.63% 1.52% 2.73% 3.13% 3.47%
FCF margin (%) - - 10.85% 8.14% 7.82% 6.3% 8.12% 9.45%
FCF / Net Income (%) - - 343.09% 1,284.45% 514.54% 230.55% 259.57% 272.06%

Profitability

        
ROA 7.79% - 3.3% 0.68% - 2.8% 4.05% 4.8%
ROE 15.04% 14.47% 6.97% 1.5% 3.57% 6.4% 7.47% 8.42%

Financial Health

        
Leverage (Debt/EBITDA) - - - - - - - -
Debt / Free cash flow - - - - - - - -

Capital Intensity

        
CAPEX / Current Assets (%) 2.65% 1.98% 1.32% 1.41% 1.6% 3.45% 2.71% 2.72%
CAPEX / EBITDA (%) 29.89% 22.85% 21.18% 13.96% 38.79% 29.6% 22.89% 21.33%
CAPEX / FCF (%) - - 12.22% 17.36% 20.51% 54.8% 33.42% 28.74%

Items per share

        
Cash flow per share 1 3.03 4.189 3.549 2.938 2.789 2.05 2.3 2.695
Change - 38.26% -15.28% -17.22% -5.06% -26.5% 12.2% 17.17%
Dividend per Share 1 0.3 0.4 0.4 0.3 0.2 0.3911 0.4596 0.5635
Change - 33.33% 0% -25% -33.33% 95.54% 17.53% 22.6%
Book Value Per Share 1 11.03 12.46 13 12.79 12.47 12.96 13.56 14.27
Change - 12.95% 4.35% -1.6% -2.5% 3.93% 4.61% 5.27%
EPS 1 1.561 1.697 0.9206 0.1927 0.4571 0.8196 0.9955 1.178
Change - 8.68% -45.74% -79.07% 137.21% 79.31% 21.45% 18.37%
Nbr of stocks (in thousands) 596,181 596,071 596,005 585,604 574,128 574,128 574,128 574,128
Announcement Date 3/14/22 3/17/23 3/19/24 4/27/25 4/28/26 - - -
1CNY
Estimates
2026 *2027 *
P/E 16.4x 13.5x
PBR 1.04x 0.99x
EV / Sales 0.31x 0.31x
Yield 2.9% 3.41%

EPS & Dividend

EPS & Dividend - Yixintang Pharmaceutical Group Co., Ltd.


Y-o-Y evolution of P/E

Valuation ratios - P/E - Yixintang Pharmaceutical Group Co., Ltd.
 

Year-on-year evolution of the Yield

Valuation ratios - Yield - Yixintang Pharmaceutical Group Co., Ltd.
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Yixintang Pharmaceutical Group Co., Ltd.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
13.48CNY
Average target price
13.71CNY
Spread / Average Target
+1.71%
  1. Stock Market
  2. Stocks
  3. 002727 Stock
  4. Financials Yixintang Pharmaceutical Group Co., Ltd.